

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Bioinformatics analyses and experimental validation of ferroptosis-related genes in bronchopulmonary dysplasia pathogenesis

Yifan Luo^{1¶}, Zongli Zhang^{2¶}, Shibing Xi^{1*}, Tao Li^{1*}

¹Department of Pediatrics, Affiliated TaiheHospital of Hubei University of Medicine, Shiyan, Hubei, China

²Institute of Pediatric Diseases, Affiliated TaiheHospital of Hubei University of Medicine, Shiyan, Hubei, China

*Correspondence Author:

Email: xishibing2009@163.com (Xi S.B.)

Email: 317371983@qq.com (Li T.)

¶These authors contributed equally to this work.

30 **Abstract**

31 **Objective**

32 We aimed to study the involvement of ferroptosis in the pathogenesis of
33 bronchopulmonary dysplasia (BPD) by conducting bioinformatics analyses and
34 identifying and validating the associated ferroptosis-related genes to explore new
35 directions for treating BPD.

36 **Methods**

37 The dataset GSE32472 on BPD was downloaded from the public genome database.
38 Using R language, differentially expressed genes (DEGs) between the BPD and
39 normal group were screened. In the present study, we adopted weighted gene
40 correlation network analysis (WGCNA) for identifying BPD-related gene modules
41 and ferroptosis-related genes were extracted from FerrDb. Their results were
42 intersected to obtain the hub genes. After that, to explore the hub gene-related
43 signaling pathways, the hub genes were exposed to gene ontology enrichment analysis.
44 With the purpose of verifying the mRNA expression of the hub genes, a single-gene
45 gene set enrichment analysis and quantitative reverse transcription polymerase chain
46 reaction were conducted. Immune cell infiltration in BPD was analyzed using the
47 CIBERSORT inverse fold product algorithm.

48 **Results**

49 A total of 606 DEGs were screened. WGCNA provided the BPD-related gene
50 module darkgreen4. The intersection of DEGs, intramodular genes, and

51 ferroptosis-related genes revealed six ferroptosis-associated hub genes (*ACSL1*,
52 *GALNT14*, *WIP11*, *MAPK14*, *PROK2*, and *CREB5*). Receiver operating characteristic
53 curve analysis demonstrated that the hub genes screened for BPD were of good
54 diagnostic significance. According to the results of immune infiltration analysis, the
55 proportions of a cluster of differentiation (CD)8, CD4 naive, and memory resting T
56 cells and M2 macrophage were elevated in the normal group, and the proportions of
57 M0 macrophage, resting mast cell, and neutrophils were increased in the BPD group.

58 **Conclusions**

59 A total of six ferroptosis-associated hub genes in BPD were identified in this study,
60 and they may be potential new therapeutic targets for BPD.

61 **1 Introduction**

62 Bronchopulmonary dysplasia (BPD) refers to a commonly seen chronic
63 respiratory disease in preterm infants, with its incidence showing negative
64 relationship to gestational age and birth weight (1, 2). There is no specific treatment
65 available for BPD. Most infants do not respond well to the present treatment. They
66 thus are prone to develop permanent pulmonary sequelae such as emphysema and
67 pulmonary hypertension and impaired physical and neurological development,
68 imposing a huge economic burden on their families and society (3-7). The study of
69 BPD pathogenesis can help provide timely intervention and treatment; thus, it is of
70 great clinical value.

71 Ferroptosis represents a novel form of cell death that is distinct from apoptosis,

72 necrosis, autophagy, as well as other forms of cell death. Usually, it can be regarded
73 as a regulated form of cell death resulted from the combined effect of lipid
74 peroxidation and iron ion accumulation. During ferroptosis, iron ions induce free
75 radical production via catalytic reactions, leading to increased oxidative stress in the
76 biological membranes and disruption of lipid metabolism, ultimately leading to cell
77 death. Ferroptosis is tightly related to various disease pathogeneses, such as
78 neurodegenerative diseases, tumors, and cardiovascular diseases related to the
79 disorders of iron metabolism (8, 9). A study found reduced levels of glutathione
80 peroxidase 4 and glutathione in the lung tissues of hyperoxia-treated neonatal rats and
81 that using ferroptosis inhibitors reduced hyperoxia-induced lung injury (10).
82 Therefore, targeted regulation of ferroptosis can be a new direction in treating BPD.

83 In the current work, we applied bioinformatics analyses to screen for
84 ferroptosis-related differentially expressed genes (DEGs) between normal children
85 and children with BPD. Additionally, we identified new targets for diagnosing and
86 treating BPD and validated them via in vitro cellular experiments.

87 **2 Materials and Methods**

88 **2.1 Microarray Data**

89 Using “Bmnchopulmonary dysplasia” as the search term, the public genomics
90 database (Gene Expression Omnibus [GEO]; <http://www.ncbi.nlm.nih.gov/geo>)
91 provided the dataset. Then, the GSE32472 dataset was selected after further filtering
92 using “Series” and “Homo sapiens” as constraints. The GPL6244 platform was used

93 to generate the GSE32472 ([HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array
94 [transcript (gene) version]). After removing the samples with no health status from the
95 dataset, data from 294 blood samples from healthy children (n = 112) and children
96 with BPD (n = 182) was obtained.

97 Ferroptosis-associated gene data were downloaded from the ferroptosis database
98 (FerrDb; <http://www.zhounan.org/ferrdb/current/>; query date: April 3, 2023), and a
99 total of 484 gene sets consisting of driver, suppressor, and marker genes were
100 acquired after the assembly and deletion of duplicate values.

101 **2.2 DEG Analysis**

102 DEGs were screened with the use of the “limma” package in the R software,
103 where the p -value of <0.05 and $|\text{fold change (FC)}| > 1.3$ could be applied to be the
104 differential gene screening conditions. The screening results were then visualized in
105 the form of volcano plots and heat maps.

106 **2.3 Weighted Gene Co-Expression Network Analysis** 107 **(WGCNA)**

108 With gene expression profiles, this study calculated the median absolute
109 deviation (MAD) of each gene, respectively. In addition, the top 50% of genes which
110 had the smallest MAD value were eliminated. The correlation coefficients between
111 genes were calculated using the WGCNA package, and the correlation coefficient
112 matrix was transformed into a neighborhood matrix, whereby a gene co-expression
113 network was constructed. With a topological overlap, the genes were clustered into

114 different modules through the nearest neighbor measure, where different modules
115 were grouped into their respective functional modules based on their intrinsic
116 commonality and similarity. The settings were as follows: minimum module size, 30;
117 sensitivity, 3; and a specific color was assigned to each module, where the grey
118 module was regarded to be the gene collection that could not be assigned to any
119 module. Using a dynamic shear tree approach, modules were identified. The module
120 feature vectors were calculated to correlate with gene expression to obtain the module
121 membership (MM), where key genes within modules were screened on the basis of
122 $|MM| > 0.8$.

123 **2.4 Hub Gene Screening and Identification**

124 Venn diagrams were drawn with an online website
125 (<https://bioinformatics.psb.ugent.be/webtools/Venn/>), and hub genes were obtained in
126 line with the intersection of DEGs, modular genes acquired by WGCNA, and the
127 ferroptosis-related gene sets. Through calculating the receiver operating characteristic
128 (ROC) curve and measuring the area under the curve (AUC), the diagnostic ability of
129 the screened hub genes could be assessed as biomarkers.

130 **2.5 Enrichment Analysis**

131 Functional enrichment analysis was adopted for investigating the underlying
132 biological mechanisms of the hub gene effect on BPD. The gene ontology (GO) of
133 these genes was analyzed. The final results were shown in the form of a chord
134 diagram with the R software. Additionally, gene set enrichment analysis (GSEA) was

135 conducted on the hub genes. The hub gene expression by the GSEA software was
136 used to classify the samples into high- ($\geq 50\%$) and low- ($< 50\%$) expression groups.
137 Using a p-value of < 0.05 and a false discovery rate of < 0.1 as screening criteria, the
138 data was downloaded from the molecular signatures database as
139 `c2.cp.kegg.v7.4.symbols.gmt` subset for assessing the relevant pathways and
140 molecular mechanisms.

141 **2.6 Immune Infiltration and Immune-Related Factors**

142 The relative proportions of 22 immune cell species in each sample in the
143 GSE32472 dataset were quantified based on the CIBERSORT method. Pearson's
144 correlation analysis was also carried out for hub genes and immune cell infiltration.

145 **2.7 Real Time Quantitative PCR (RT-qPCR)**

146 The human lung adenocarcinoma epithelial cell line A549 was cultivated in
147 Dulbecco's modified Eagle medium including 10% fetal bovine serum (11995500,
148 Gibco). The cells were divided into two groups, where one was treated at a high
149 oxygen concentration (85%) and the other at an oxygen concentration of 21%. At 0,
150 12, 24, and 48 h following the treatment, the total RNA was extracted with TRIzol
151 (DP424, TIANGEN), reverse transcription was conducted with the Reverse
152 Transcription Kit (R122-01, Vazyme). The real-time quantitative polymerase chain
153 reaction (RT-qPCR) was made with the Taq pro universal SYBR qPCR master mix
154 (Q712-02, Vazyme). With β -actin being an internal reference, we adopted the $2^{-\Delta\Delta Ct}$
155 method for calculating the relative expression of target genes. The primers were

156 designed at the National Center for Biotechnology Information website
157 (<https://www.ncbi.nlm.nih.gov/>) and synthesized at Shanghai Bioengineering Co.
158 Table 1 presents the primer sequences.

159 **2.8 Cell Survival Rate**

160 The cells were divided into control and model groups, inoculated in 96-well
161 plates, 6 replicate wells were set up for each group of cells, 100ul of cell suspension
162 was supplemented to each well, 21% oxygen stimulation was given to the control
163 group, 85% oxygen stimulation was given to the model group, 10ul of CCK8 working
164 solution was supplemented to each well after 48h, incubated in the incubator for 1h,
165 and the absorbance value at 450nm was measured with the use of enzyme marker.

166 **2.9 Statistical Analysis**

167 Based on R software, we carried out all statistical analyses. Student's *t*-tests were
168 adopted for analyzing the significance of differential expression of ferroptosis-related
169 genes in the GEO dataset. In order to compare gene expression between samples in
170 cellular experiments, one-way analysis of variance was adopted. Pearson's correlation
171 analysis was employed to analyze the relationship between hub genes and immune
172 cell infiltration. In addition, the *p*-value of <0.05 was thought to be of statistical
173 significance.

174 **3 Results**

175 **3.1 Onset of Ferroptosis in a Hyperoxia-Induced BPD**

176 **Model**

177 In a previous experiment in which we constructed an in vitro model of BPD
178 using hyperoxia in A549 epithelial cells, we found that a large number of cells died
179 after 48 h of hyperoxia stimulation, and also observed uneven distribution of cells
180 with different morphology and size (Figs 1A and 1B). Combined with the previous
181 literature reporting that the use of iron death inhibitors could reduce
182 hyperoxia-induced lung tissue injury, it was speculated that hyperoxia could induce
183 ferroptosis to promote the occurrence and development of BPD. And by RT-qPCR
184 assay, we decreased mRNA expression of two each classical ferroptosis marker
185 glutathione peroxidase 4 (GPX4) and increased expression levels of
186 prostaglandin-endoperoxide synthase 2 (PTGS2) were detected in cells after 48 h of
187 hyperoxia treatment with p -value < 0.01. (Fig 1C).

188 **3.2 Ferroptosis-Related DEGs in GSE32472**

189 To further investigate the role of ferroptosis in BPD, bioinformatics techniques
190 were used to screen for ferroptosis-related genes in BPD. Totally 606 DEGs were
191 acquired from the GSE32472 dataset, containing 354 upregulated and 252
192 downregulated genes (Figs 2A and 2B). With the soft threshold power being at 10, the
193 independence scale reached 0.86, and the average linkage value was 22.52 (Figs 3B
194 and 3C). Totally 27 different co-expression modules were acquired through dynamic
195 tree cutting with the cut height being set to 0.25, and the minimum module size being
196 set to 30 (Fig 3E). The modules were then analyzed for correlation with clinical

197 features. The darkgreen4 module was highly related to BPD ($r = 0.40$, $p = 7.9e-13$,
198 Fig 3D), indicating that genes in this module may be associated with a relevant
199 biological function. Additionally, genomic and BPD phenotypes were significantly
200 correlated in the darkgreen4 module ($r = 0.75$, $p = 2.0e-107$, Fig 3F). With the
201 module membership (MM) > 0.8 and gene significance (GS) > 0.2 being screening
202 conditions, totally 187 genes were obtained from the darkgreen4 module. These 187
203 genes were crossed with 606 DEGs and 484 ferroptosis-related genes, and finally, six
204 hub genes were obtained (Fig 4A). Violin plots showed that in the GSE32472 dataset,
205 the expression of all six genes was discovered to be reduced in the BPD group in
206 relative to the control group (Fig 5).

207 **3.3 Cellular experimental Validation of Hub Genes**

208 To demonstrate the mRNA expression of four hub genes, RT-qPCR was carried
209 out. The findings demonstrated reduced expression of *ACSL1*, *GALNT14*, *WIP1I*, and
210 *MAPK14* in the hyperoxia model group in relative to the blank control group, and
211 $p\text{-value} < 0.05$ (Fig 6).

212 **3.4 Functional enrichment Analysis of Hub Genes**

213 To explain the hub gene-associated biological functions and pathways, GO
214 enrichment analysis was made (Fig 4B). According to the results, three of the six
215 ferroptosis-related differential hub genes were involved in “mitogen-activated protein
216 kinase (MAPK) p38 binding,” “nuclear factor of activated T cell protein binding,”
217 “medium-chain fatty acid-coenzyme ligase activity,” “decanoic acid coenzyme ligase

218 activity,” and “acyl coenzyme ligase activity,” “MAPK activity,” “long-chain fatty
219 acid-coenzyme ligase activity,” “fatty acid ligase activity,” “polypeptide n-acetyl
220 galactosyltransferase activity,” and other functions.

221 Single-gene GSEA–Kyoto encyclopedia of genes and genomes pathway analysis
222 was adopted for assessing the correlation of BPD with hub genes. Figs 7A–7E
223 illustrate the five major pathways enriched for each hub gene. Of these, ACSL1 was
224 related to the peroxisome proliferator-activated receptor (PPAR) signaling pathway,
225 antigen processing and delivery, shear bodies, complement and coagulation cascades,
226 and the insulin signaling pathway. CREB5 was related to the gonadotropin-releasing
227 hormone signaling pathway, dorsal–ventral axis formation, MAPK signaling pathway,
228 regulation of the actin cytoskeleton, and ribosomes. GALNT14 was associated with
229 ribosomes, autoimmune thyroid disease, cell adhesion molecules, cysteine MAPK14
230 (related to type 2 diabetes), glycerophospholipid metabolism, PPAR signaling
231 pathway, transendothelial migration of leukocytes, and actin cytoskeleton regulation.
232 PROK2 was related to pyruvate metabolism, autoimmune thyroid disease, N-glycan
233 biosynthesis, valine, leucine, and isoleucine degradation, and antigen processing and
234 delivery. WIPI1 was associated with glycerophospholipid metabolism, sucrose, and
235 starch metabolism, epithelial cell signaling in *Helicobacter pylori* infection,
236 endocytosis, and cancer pathways.

237 **3.5 ROC Curve Analysis for Hub Genes**

238 To build regression models on the basis of six marker genes, the glmnet package

239 in the R software was applied. ROC curves showed that the model was able to
240 distinguish between the control and BPD group samples (AUC = 0.787, Fig 8A). In
241 addition, ROC curves were adopted for assessing the correlation between individual
242 genes and BPD, with each gene having an AUC value of >0.6 (Fig 8B). The findings
243 demonstrated that in relative to the individual marker genes, the logistic regression
244 model showed a higher level of specificity and accuracy.

245 **3.6 Immuno-Infiltration Analysis**

246 The microenvironment is consisted of immune cells, extracellular matrix, and
247 inflammatory and diverse growth factors and has vital implications for clinical
248 treatment sensitivity and disease diagnosis. Using the CIBERSORT algorithm, the
249 naïve proportions of 22 immune cells across the 112 control samples and 182 BPD
250 samples were estimated and are presented in the bar and violin plots (Figs 9A, 9B).
251 Compared with the control samples, the BPD samples showed increased proportions
252 of M0 macrophages, resting type mast cells, and neutrophils. In contrast, a cluster of
253 differentiation (CD)8, Cnaïveive and memory resting T cells, and M2 macrophage
254 proportions were reduced. According to Pearson's correlation analysis, there existed
255 significant negative and positive correlations between ACSL1, GALNT14, WIPI1,
256 MAPK14, PROK2, CREB5 and CD8 T cells, CD4-naive T cells, CD4 memory T cells,
257 M0 macrophage, and neutrophils (Fig 10).

258 **4 Discussion**

259 Novel BPD is a disease that primarily presents with impaired alveolar capillary

260 development, alveolar enlargement and simplification, increased interstitial fibrosis,
261 pulmonary vascular abnormalities, and reduced branching (11). The pathogenesis of
262 this disease is not completely understood. However, some studies have indicated that
263 oxidative stress refers to one of the important mechanisms in the pathogenesis of BPD
264 (12-14). Long-term hyperoxia exposure induces oxidative stress, which affects
265 alveolar development and angiogenesis. Furthermore, oxidative stress leads to the
266 accumulation of oxygen radicals and other reactive oxygen products in lung cells,
267 thereby damaging cell structure and leading to cell death and, ultimately, BPD (15,
268 16). Therefore, inhibiting the oxidative/antioxidative imbalance in BPD and
269 decreasing cell death may be a new therapeutic direction in the future.

270 As a recently found form of cell death, ferroptosis is featured by an
271 iron-dependent increase in lipid peroxidation because of reactive oxygen species (17).
272 Iron is widely present in life and is one of the elements essential for cell metabolism
273 and growth. However, when there is an excess of iron ions in cells, large amounts of
274 oxygen radicals and cytotoxic reactions are generated, which leads to cell damage and
275 death. There existed a decrease in the number of cells in the model group with
276 variable changes in cell morphology during the construction of a hyperoxic BPD cell
277 model, and also detected a decrease in GPX4 mRNA expression and an upregulation
278 of PTGS2 expression in the model group, which has not been reported before. In
279 addition, Cross et al. (18, 19) reported that free iron concentrations in cord blood were
280 significantly higher in preterm infants than in full-term infants and adults. Patel et al.
281 (20) reported that increased cumulative iron supplementation in very low birth weight

282 infants is an independent risk factor for BPD. Moreover, BPD is most commonly
283 observed in preterm infants and is a crucial factor in preterm mortality and poor
284 long-term prognosis. We therefore hypothesize that abnormal accumulation of iron in
285 preterm infants may induce the onset of ferroptosis thereby promoting the
286 development of BPD.

287 On this basis, this study further clarifies the function of ferroptosis in the
288 development of BPD. 606 DEGs of BPD were obtained from the GEO database,
289 disease key modules were acquired using WGCNA analysis, 197 differential genes
290 within modules were obtained after the screening, and 484 ferroptosis-related genes
291 were acquired from the FerrDb database. There were intersected to finally obtain 6
292 hub genes related to ferroptosis in BPD, which included the following: *ACSL1*,
293 *GALNT14*, *WIPI1*, *MAPK14*, *PROK2*, and *CREB5*.

294 The ACSL family is a vital enzyme in fatty acid synthesis and catabolism.
295 ACSL1 is mainly distributed in adipose and muscle tissues in humans and makes a
296 crucial role in cellular energy metabolism and fatty acid metabolism. Zhang et al. (21)
297 reported that ACSL1 decreased intracellular lipid peroxidation levels and resisted the
298 development of ferroptosis during ovarian cancer metastasis. In this study,
299 bioinformatics analyses revealed that ACSL1 as a ferroptosis gene was decreased in
300 samples from the BPD group of the GEO dataset. qPCR validated the results to be
301 consistent; therefore, we hypothesized that in children with BPD, downregulated
302 ACSL1 promotes ferroptosis and participates in disease progression. *GALNT14* is a
303 member of the peptide N-acetylgalactosaminyltransferase (ppGalNAc-Ts). These

304 enzymes can catalyze the transfer of N-acetyl-D-galactosamine (GalNAc) to hydroxyl
305 groups on Serine and Threonine in target peptides, initiating protein O-glycosylation
306 and affecting tumorigenesis and progression (22). Li et al. (23) reported that the
307 downregulation of GALNT14 induced cellular ferroptosis by inhibiting mTOR
308 activity. In this study, a BPD model was constructed using hyperoxia-stimulated A549
309 cells, and qPCR was performed to determine whether GALNT14 expression gradually
310 decreased with the prolongation of hyperoxia stimulation, conforming to the trend of
311 microarray analysis, indicating that GALNT14 may be engaged in BPD development
312 through the induction of ferroptosis. WIPI1 is a protein involved in the process of
313 cellular autophagy and is a member of the cofactor protein family. The main role of
314 WIPI1 is to interact with PI3K-III during the formation of autophagosomal
315 membranes and to assist in their localization to the initiation site of autophagosomal
316 membranes, which triggers the autophagic process (24). Deneubourg et al. (25)
317 proposed that in Parkinson's disease, Huntington's disease, and other
318 neurodegenerative diseases, the deletion of autophagy-related genes leads to the
319 accumulation of abnormal protein and autophagic vesicles, disrupting neuronal
320 homeostasis and ultimately leading to cell death. In this study, we screened WIPI1 as
321 a hub gene in BPD by microarray analysis and found that WIPI1 expression was
322 notably reduced in lung epithelial cells after hyperoxia treatment; as a result, we
323 speculate that WIPI1 may be involved in cell death in BPD. MAPK14 is a
324 serine–threonine protein kinase which is a member of the p38MAPK subfamily.
325 MAPK14 makes a vital regulatory role in various diseases, including pneumonia and

326 acute lung injury, and inhibition of this pathway can alleviate inflammatory responses
327 and oxidative stress levels in disease states (26). Furthermore, the p38 MAPK
328 signaling pathway is also engaged in regulating various angiogenic regulators,
329 including VEGF, bFGF, and PDGF, affecting the proliferation, migration, and
330 angiogenic capacity of endothelial cells (27, 28). This study focused on constructing a
331 BPD cell model and found that MAPK14 expression reduced at 12 and 24 h of
332 hyperoxia stimulation but returned to unstimulated levels after 48 h of stimulation,
333 suggesting that MAPK14 may inhibit the oxidative stress response in vivo at the early
334 stage of BPD, but gradually increased as the organism was in an uncompensated
335 state. PROK2, a member of the prokineticin family, is a neuropeptide hormone that is
336 involved as a cytokine in diverse physiological and pathological processes, including
337 reproductive and neurodevelopment, angiogenesis, immune response, and
338 inflammatory response. In the circulatory system, PROK2 is involved in regulating
339 angiogenesis and vascular function, and regulates blood pressure and cardiac function
340 (29). Bao et al. (30) reported that treating primary neuronal cells with the ferroptosis
341 inducer Erastin increased PROK2 expression and protected mitochondrial function.
342 Furthermore, PROK2 is mainly involved in activating and chemotaxis of monocytes
343 and T cells in immune and inflammatory responses (31, 32). Wang et al. (33)
344 identified a neutrophil subtype with high PROK2 expression in the lung vessels of
345 ALI mice, which exhibited an immune-activated state and could resist pathogens.
346 CREB5 belongs to a family of CRE (cAMP response element) binding proteins that
347 encode proteins that bind CRE specifically to c-Jun or CRE-BP1 as homodimers or

348 heterodimers and function as CRE-dependent trans-activators, regulating metabolism,
349 cell cycle, growth factors, immune regulation, reproductive development, signal
350 transduction, and other related biological processes (34-36). Gu et al. (37) reported
351 that AG1296 increased CREB5 expression in PAH lung vessels and promoted
352 angiogenesis. Based on the above studies, it is hypothesized that ACSL1, GALNT14,
353 WIPI1, MAPK14, PROK2, and CREB5 may be involved in BPD progression by
354 mediating cell death, oxidative stress, or regulating angiogenesis. However, the
355 specific mechanisms between these genes and BPD require further investigation.

356 Furthermore, as the immune system is not completely developed in preterm
357 infants, exposure to various risk factors, such as prenatal and postnatal infections,
358 hyperoxia, and mechanical ventilation, leads to oxidative stress in the functionally
359 immature lungs, increased expression of proinflammatory cytokines, recruitment of
360 neutrophils as the first line of immune defense, and subsequent release of chemokines
361 to recruit monocytes to adhere to endothelial cells and promote their extravasation and
362 differentiation into macrophages and ultimately compromise epithelial and vascular
363 function (38). Furthermore, mast cells can disrupt angiogenesis in rat and mouse
364 models of hyperoxia stress (39-42). However, prolonged exposure to hyperoxia
365 reduces the number of CD4⁺ and CD8⁺ T cells, which results in defective T cell
366 development in the thymus (43). In this study, the number of T cells CD8 and CD4
367 and macrophages M2 in BPD was found to be less than the control group. By the
368 CIBERSORT method, the number of macrophages M0, mast cells, and neutrophils
369 was higher than the control group. Furthermore, we found that ACSL1, GALNT14,

370 WIPI1, MAPK14, PROK2, and CREB5 were associated with these immune cells.

371 This study has some limitations that should be addressed. We selected only one
372 dataset for analysis and validated the characteristics of the hub ferroptosis-related
373 genes in an external dataset. Owing to the difficulties in obtaining samples, we only
374 performed *in vitro* cellular experiments to validate these genes, which will be further
375 validated using animal models. Therefore, further corroboration in clinical practice is
376 still required.

377 **5 Conclusions**

378 Through a bioinformatics approach, we identified six hub genes associated with
379 ferroptosis in BPD (*ACSL1*, *GALNT14*, *WIPI1*, *MAPK14*, *PROK2*, and *CREB5*),
380 which were additionally found to be associated with immune cells. Moreover, our
381 findings offer a novel idea for studying the pathogenesis of BPD.

382

383 **Acknowledgments**

384 We thank all authors for their contributions to this research.

385

386 **References**

- 387 1. Sabatelli D, Milet B, Mena P, Domínguez A. Growth restriction increases the risk
388 of bronchopulmonary dysplasia, death, and sepsis in twins of 30 weeks or less of

- 389 gestation. *Rev Chil Pediatr.* 2019;90(1):36-43. doi:10.32641/rchped.v90i1.840
- 390 2. Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of
391 bronchopulmonary dysplasia among extremely preterm infants: a systematic
392 literature review. *J Matern Fetal Neonatal Med.* 2021;34(11):1721-31.
393 doi:10.1080/14767058.2019.1646240
- 394 3. Koltsida G, Konstantinopoulou S. Long term outcomes in chronic lung disease
395 requiring tracheostomy and chronic mechanical ventilation. *Semin Fetal
396 Neonatal Med.* 2019;24(5):101044. doi:10.1016/j.siny.2019.101044
- 397 4. Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental
398 outcomes of bronchopulmonary dysplasia. *Semin Perinatol.* 2018;42(7):478-84.
399 doi:10.1053/j.semperi.2018.09.013
- 400 5. DeMauro SB. The Impact of Bronchopulmonary Dysplasia on Childhood
401 Outcomes. *Clin Perinatol.* 2018;45(3):439-52. doi:10.1016/j.clp.2018.05.006
- 402 6. Doyle LW, Cheong JL, Hay S, Manley BJ, Halliday HL. Late (≥ 7 days)
403 systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia
404 in preterm infants. *Cochrane Database Syst Rev.* 2021;11(11):Cd001145.
405 doi:10.1002/14651858.CD001145.pub5
- 406 7. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal
407 Administration of Budesonide/Surfactant to Prevent Bronchopulmonary
408 Dysplasia. *Am J Respir Crit Care Med.* 2016;193(1):86-95.
409 doi:10.1164/rccm.201505-0861OC

- 410 8. Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of
411 iron and ferroptosis in cardiovascular disease. *Nat Rev Cardiol.* 2023;20(1):7-23.
412 doi:10.1038/s41569-022-00735-4
- 413 9. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in
414 disease. *Nat Rev Mol Cell Biol.* 2021;22(4):266-82.
415 doi:10.1038/s41580-020-00324-8
- 416 10. Jia D, Zheng J, Zhou Y, Jia J, Ye X, Zhou B, et al. Ferroptosis is Involved in
417 Hyperoxic Lung Injury in Neonatal Rats. *J Inflamm Res.* 2021;14:5393-401.
418 doi:10.2147/jir.S335061
- 419 11. Principi N, Di Pietro GM, Esposito S. Bronchopulmonary dysplasia: clinical
420 aspects and preventive and therapeutic strategies. *J Transl Med.* 2018;16(1):36.
421 doi:10.1186/s12967-018-1417-7
- 422 12. Wang J, Dong W. Oxidative stress and bronchopulmonary dysplasia. *Gene.*
423 2018;678:177-83. doi:10.1016/j.gene.2018.08.031
- 424 13. Cannavò L, Perrone S, Viola V, Marseglia L, Di Rosa G, Gitto E. Oxidative
425 Stress and Respiratory Diseases in Preterm Newborns. *Int J Mol Sci.*
426 2021;22(22). doi:10.3390/ijms222212504
- 427 14. Kimble A, Robbins ME, Perez M. Pathogenesis of Bronchopulmonary Dysplasia:
428 Role of Oxidative Stress from 'Omics' Studies. *Antioxidants (Basel).* 2022;11(12).
429 doi:10.3390/antiox11122380
- 430 15. Mathias M, Chang J, Perez M, Saugstad O. Supplemental Oxygen in the

- 431 Newborn: Historical Perspective and Current Trends. *Antioxidants* (Basel).
432 2021;10(12). doi:10.3390/antiox10121879
- 433 16. Yang X, Jiang S, Deng X, Luo Z, Chen A, Yu R. Effects of Antioxidants in
434 Human Milk on Bronchopulmonary Dysplasia Prevention and Treatment: A
435 Review. *Front Nutr*. 2022;9:924036. doi:10.3389/fnut.2022.924036
- 436 17. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et
437 al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*.
438 2012;149(5):1060-72. doi:10.1016/j.cell.2012.03.042
- 439 18. Cross JH, Prentice AM, Cerami C. Hepcidin, Serum Iron, and Transferrin
440 Saturation in Full-Term and Premature Infants during the First Month of Life: A
441 State-of-the-Art Review of Existing Evidence in Humans. *Curr Dev Nutr*.
442 2020;4(8):nzaa104. doi:10.1093/cdn/nzaa104
- 443 19. Deng X, Bao Z, Yang X, Mei Y, Zhou Q, Chen A, et al. Molecular mechanisms
444 of cell death in bronchopulmonary dysplasia. *Apoptosis*. 2023;28(1-2):39-54.
445 doi:10.1007/s10495-022-01791-4
- 446 20. Patel RM, Knezevic A, Yang J, Shenvi N, Hinkes M, Roback JD, et al. Enteral
447 iron supplementation, red blood cell transfusion, and risk of bronchopulmonary
448 dysplasia in very-low-birth-weight infants. *Transfusion*. 2019;59(5):1675-82.
449 doi:10.1111/trf.15216
- 450 21. Zhang Q, Li N, Deng L, Jiang X, Zhang Y, Lee LTO, et al. ACSL1-induced
451 ferroptosis and platinum resistance in ovarian cancer by increasing FSP1

- 452 N-myristylation and stability. *Cell Death Discov.* 2023;9(1):83.
453 doi:10.1038/s41420-023-01385-2
- 454 22. Lin WR, Yeh CT. GALNT14: An Emerging Marker Capable of Predicting
455 Therapeutic Outcomes in Multiple Cancers. *Int J Mol Sci.* 2020;21(4).
456 doi:10.3390/ijms21041491
- 457 23. Li HW, Liu MB, Jiang X, Song T, Feng SX, Wu JY, et al. GALNT14 regulates
458 ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway.
459 *Future Oncol.* 2022;18(2):149-61. doi:10.2217/fon-2021-0883
- 460 24. Almannai M, Marafi D, El-Hattab AW. WIPI proteins: Biological functions and
461 related syndromes. *Front Mol Neurosci.* 2022;15:1011918.
462 doi:10.3389/fnmol.2022.1011918
- 463 25. Deneubourg C, Ramm M, Smith LJ, Baron O, Singh K, Byrne SC, et al. The
464 spectrum of neurodevelopmental, neuromuscular and neurodegenerative
465 disorders due to defective autophagy. *Autophagy.* 2022;18(3):496-517.
466 doi:10.1080/15548627.2021.1943177
- 467 26. Corre I, Paris F, Huot J. The p38 pathway, a major pleiotropic cascade that
468 transduces stress and metastatic signals in endothelial cells. *Oncotarget.*
469 2017;8(33):55684-714. doi:10.18632/oncotarget.18264
- 470 27. Avila-Carrasco L, Majano P, Sánchez-Toméro JA, Selgas R, López-Cabrera M,
471 Aguilera A, et al. Natural Plants Compounds as Modulators of
472 Epithelial-to-Mesenchymal Transition. *Front Pharmacol.* 2019;10:715.

473 doi:10.3389/fphar.2019.00715

474 28. Edatt L, Poyyakkara A, Raji GR, Ramachandran V, Shankar SS, Kumar VBS.

475 Role of Sirtuins in Tumor Angiogenesis. *Front Oncol.* 2019;9:1516.

476 doi:10.3389/fonc.2019.01516

477 29. Negri L, Ferrara N. The Prokineticins: Neuromodulators and Mediators of

478 Inflammation and Myeloid Cell-Dependent Angiogenesis. *Physiol Rev.*

479 2018;98(2):1055-82. doi:10.1152/physrev.00012.2017

480 30. Bao Z, Liu Y, Chen B, Miao Z, Tu Y, Li C, et al. Prokineticin-2 prevents

481 neuronal cell deaths in a model of traumatic brain injury. *Nat Commun.*

482 2021;12(1):4220. doi:10.1038/s41467-021-24469-y

483 31. Negri L, Maftai D. Targeting the Prokineticin System to Control Chronic Pain

484 and Inflammation. *Curr Med Chem.* 2018;25(32):3883-94.

485 doi:10.2174/0929867324666170713102514

486 32. Monnier J, Quillien V, Piquet-Pellorce C, Leberre C, Preisser L, Gascan H, et al.

487 Prokineticin 1 induces CCL4, CXCL1 and CXCL8 in human monocytes but not

488 in macrophages and dendritic cells. *Eur Cytokine Netw.* 2008;19(4):166-75.

489 doi:10.1684/ecn.2008.0138

490 33. Wang K, Wang M, Liao X, Gao S, Hua J, Wu X, et al. Locally organised and

491 activated Fth1(hi) neutrophils aggravate inflammation of acute lung injury in an

492 IL-10-dependent manner. *Nat Commun.* 2022;13(1):7703.

493 doi:10.1038/s41467-022-35492-y

- 494 34. Acquarone E, Argyrousi EK, van den Berg M, Gulisano W, Fà M, Staniszewski
495 A, et al. Synaptic and memory dysfunction induced by tau oligomers is rescued
496 by up-regulation of the nitric oxide cascade. *Mol Neurodegener.* 2019;14(1):26.
497 doi:10.1186/s13024-019-0326-4
- 498 35. Yan K, Gao LN, Cui YL, Zhang Y, Zhou X. The cyclic AMP signaling pathway:
499 Exploring targets for successful drug discovery (Review). *Mol Med Rep.*
500 2016;13(5):3715-23. doi:10.3892/mmr.2016.5005
- 501 36. Lonze BE, Ginty DD. Function and regulation of CREB family transcription
502 factors in the nervous system. *Neuron.* 2002;35(4):605-23.
503 doi:10.1016/s0896-6273(02)00828-0
- 504 37. Gu M, Donato M, Guo M, Wary N, Miao Y, Mao S, et al. iPSC-endothelial cell
505 phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for
506 pulmonary arterial hypertension. *Sci Transl Med.* 2021;13(592).
507 doi:10.1126/scitranslmed.aba6480
- 508 38. Heydarian M, Schulz C, Stoeger T, Hilgendorff A. Association of immune cell
509 recruitment and BPD development. *Mol Cell Pediatr.* 2022;9(1):16.
510 doi:10.1186/s40348-022-00148-w
- 511 39. Veerappan A, Thompson M, Savage AR, Silverman ML, Chan WS, Sung B, et al.
512 Mast cells and exosomes in hyperoxia-induced neonatal lung disease. *Am J*
513 *Physiol Lung Cell Mol Physiol.* 2016;310(11):L1218-32.
514 doi:10.1152/ajplung.00299.2015

- 515 40. de Souza Junior DA, Borges AC, Santana AC, Oliver C, Jamur MC. Mast Cell
516 Proteases 6 and 7 Stimulate Angiogenesis by Inducing Endothelial Cells to
517 Release Angiogenic Factors. PLoS One. 2015;10(12):e0144081.
518 doi:10.1371/journal.pone.0144081
- 519 41. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The Role of
520 Mast Cell Specific Chymases and Trypsases in Tumor Angiogenesis. Biomed Res
521 Int. 2015;2015:142359. doi:10.1155/2015/142359
- 522 42. Ren Y, Lyu Y, Mereness JA, Wang S, Pang J, Mariani TJ. Rare Pulmonary
523 Connective Tissue Type Mast Cells Regulate Lung Endothelial Cell
524 Angiogenesis. Am J Pathol. 2020;190(8):1763-73.
525 doi:10.1016/j.ajpath.2020.04.017
- 526 43. Angusamy S, Mansour T, Abdulmageed M, Han R, Schutte BC, LaPres J, et al.
527 Altered thymocyte and T cell development in neonatal mice with
528 hyperoxia-induced lung injury. J Perinat Med. 2018;46(4):441-9.
529 doi:10.1515/jpm-2016-0234

530

531 **Supporting information**

532 **S1 Fig .Hyperoxia promotes BPD by inducing ferroptosis.** (A) Morphological
533 images of A549 cells. (B) CCK8 method to detect the effect of hyperoxia stimulation
534 for 48h on the viability of A549 cells. (C) Detection of GPX4, PTGS2 mRNA
535 expression by RT-qPCR after hyperoxia (oxygen concentration of 85%) stimulation of

536 A549 cells for 48h. $**P < 0.01$, $***P < 0.001$, compared to the control (oxygen
537 concentration of 21%) group.

538 **S2 Fig . Identification of DEGs.** (A) The volcano plot of DEGs between the BPD
539 and control groups in the GSE32472 dataset. (B) The heatmap of the top 20 DEGs
540 between the BPD and control groups in the GSE32472 dataset.

541 **S3 Fig . Identification of key module genes in WGCNA.** (A) Sample clustering
542 dendrogram. (B) The analysis of scale-free fit index for different soft threshold cases.
543 (C) The analysis of average connectivity for different soft thresholds. (D) Heatmap of
544 the relationship between gene modules and sample information; the various colors
545 represent the different modules. (E) Gene clustering tree diagram based on the
546 co-expression networks constructed with optimal soft thresholds after classifying
547 genes into different modules. (F) Scatter plot of GS and MM correlations for
548 darkgreen4 module.

549 **S4 Fig .Identification of the ferroptosis-related DEGs genes and GO enrichment**
550 **analyses of hub genes.** (A) Venn diagram of all DEGs, darkgreen4 module genes in
551 WGCNA, and ferroptosis genes from the FerrDb database. (B) Circle diagram for GO
552 enrichment analysis of hub genes.

553 **S5 Fig .Violin plot showing the levels of six hub genes in BPD and control**
554 **samples of the dataset GSE32472.** (A) ACSL1. (B)GALNT14. (C) WIPI1. (D)
555 MAPK14. (E) PROK2. (F)CREB5

556 **S6 Fig .Validation of mRNA expression of selected hub genes.**

557 (A)ACSL1.(B)GALNT14. (C) WIPI1. (D) MAPK14.where* $P < 0.05$, ** $P < 0.01$,

558 *** $P < 0.001$, when compared with the control (0 h) group.

559 **S7 Fig .Single-gene GSEA enrichment analysis.**(A) ACSL1.(B)GALNT14. (C)

560 WIPI1. (D) MAPK14. (E) PROK2. (F) CREB5.Note: six major pathways were

561 selected for each gene.

562 **S8 Fig . ROC curve analysis of 6 hub genes.** (A) Evaluation of the logistic

563 regression models for joint diagnostic markers to identify disease samples in the

564 GSE32472 dataset. (B) Evaluation of 6 hub genes to identify the disease samples in

565 the GSE32472 dataset.

566 **S9 Fig . Immune infiltration analysis.** (A) Bar chart showing the proportion of 22

567 immune cell types in each sample. (B) Expression of different immune cells between

568 the BPD and control groups, where* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P <$



569 0.0001, compared with the control group.

570 **S10 Fig . Correlation between the six hub genes and immune infiltration.**



571 **S1 Table. Primer sequences.**

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
GPX4	GCCTTTGCCGCCTACTGAA	TTAACCATGTGCCCGTCGAT
PTGS2	CTCCCTTGGGTGTCAAAGGTAA	GTGCTGGGCAAAGAATGCAA
ACSL1	AAGTGGA ACTACAGGCAACCC	AGTATCATCTGGGCAAGGATTGA
GALNT14	TGCAGACCCCTAAGCCTTC	GATTGCTGGAGATCCGCTCA
WIPI1	ACCAGGACTGCACATCCCTA	TCATTGCTTCCGTGGACTTGA


MAPK14	TCAGCAGATTATGCGTCTGACA	AAGTCGACAGCCAGGGGA
β -action	AAACTGGAACGGTGAAGGTG	AGAGAAGTGGGGTGGCTTTT





Figure




Figure







Figure




Figure





Figure





Figure





Figure




Figure



Figure



Figure






Figure

Control




Hyperoxia

Hyperoxia+Fer-1

Hoechst




PI




Figure


Control





Hyperoxia




Hyperoxia+Fer-1



ROS



Figure



Figure